Mineralocorticoid receptor antagonists use in patients with heart failure and impaired renal function.
<h4>Aims</h4>Impaired renal function is a major contributor to the low proportion of mineralocorticoid receptor antagonist (MRA) treatment in patients with heart failure with reduced ejection fraction (HFrEF). Our aims were to investigate the impact of MRA treatment on all-cause mortalit...
Saved in:
Main Authors: | Anna Jonsson Holmdahl, Helena Norberg, Fredrik Valham, Ellinor Bergdahl, Krister Lindmark |
---|---|
Format: | article |
Language: | EN |
Published: |
Public Library of Science (PLoS)
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/87f3747ff87c4b64a863204fda7adadc |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Mineralocorticoid receptor antagonists use in patients with heart failure and impaired renal function
by: Anna Jonsson Holmdahl, et al.
Published: (2021) -
New clinical opportunities for mineralocorticoid receptor antagonists: focus on antifibrotic effects
by: Natalia A. Dragomiretskaya, et al.
Published: (2021) -
Predictive factors of selective mineralocorticoid receptor antagonist treatment in chronic central serous chorioretinopathy
by: Róbert Gergely, et al.
Published: (2020) -
A novel mineralocorticoid receptor antagonist, 7,3',4'-trihydroxyisoflavone improves skin barrier function impaired by endogenous or exogenous glucocorticoids
by: Hanil Lee, et al.
Published: (2021) -
Oral mineralocorticoid antagonists for recalcitrant central serous chorioretinopathy
by: Chin EK, et al.
Published: (2015)